Trial Profile
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Ductal carcinoma; Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms TEACH
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development
- 01 Jun 2019 Trial has been completed in UK according to European Clinical Trials Database record.
- 29 Jan 2016 Subgroup analysis (n=2489) published in the European Journal of Cancer.
- 03 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.